Rubfila International Ratios

Rubfila International Ltd Ratios

The Rubfila International Ltd Ratios page provides a complete fundamental analysis of Rubfila International Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Rubfila International Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Rubfila International Ltd (NSE: RUBFILA, BSE: 500367) is currently trading at ₹63.90, with a market capitalization of ₹3.43B. As a major player in the Process industries sector and Industrial specialties industry, Rubfila International Ltd remains a key stock for fundamental analysis using Rubfila International Ltd Ratios.

Rubfila International Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Rubfila International Ltd P/E ratio currently stands at 11.71, making it one of the most tracked metrics in Rubfila International Ltd Ratios.

Historically, the Rubfila International Ltd P/E ratio has shown strong fluctuations:

• 2024: 11.71
• 2023: 14.56
• 2022: 12.92
• 2021: 11.20
• 2020: 9.20

The decline in Rubfila International Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Rubfila International Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.17.

Historical P/B trend:

• 2024: 1.17
• 2023: 1.37
• 2022: 1.33
• 2021: 2.12

Rubfila International Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Rubfila International Ltd P/S ratio currently stands at 0.63, an important part of Rubfila International Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.63
• 2023: 0.79
• 2022: 0.73
• 2021: 1.05

A stable or declining Rubfila International Ltd P/S ratio indicates cautious market sentiment.

Rubfila International Ltd Price to Cash Flow Ratio (P/CF)

The Rubfila International Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 11.61.

Historical Rubfila International Ltd Price to Cash Flow Ratio:

• 2024: 11.61
• 2023: 11.91
• 2022: 11.48
• 2021: 12.99
• 2020: 16.46

The declining Rubfila International Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Rubfila International Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Rubfila International Ltd EV currently stands at ₹3B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3B
• 2023: 3.41B
• 2022: 3.3B
• 2021: 4.87B

Rubfila International Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Rubfila International Ltd EV/EBITDA ratio is currently 6.40, a key metric in Rubfila International Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 6.40
• 2023: 8.95
• 2022: 8.34
• 2021: 7.22

Stable Rubfila International Ltd EV/EBITDA indicates balanced valuation.

Rubfila International Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Rubfila International Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Rubfila International Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Rubfila International Ltd ROE currently stands at 10.43%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 10.43
• 2023: 9.72
• 2022: 10.65
• 2021: 20.64

Rubfila International Ltd maintains stable profitability levels.

Rubfila International Ltd Ratios Analysis Summary

The Rubfila International Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Rubfila International Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Rubfila International Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.